...
首页> 外文期刊>Clinical ophthalmology >Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication
【24h】

Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication

机译:在开角型青光眼受试者中使用局部降压药物对一,二或三个小梁旁路支架进行前瞻性,随机研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To assess the safety and efficacy of one, two, or three trabecular microbypass stents in eyes with primary open-angle glaucoma (OAG) not controlled on ocular hypotensive medication. A total of 119 subjects were followed for 18?months postoperatively. Materials and methods: Subjects with medicated intraocular pressure (IOP) 18–30?mmHg and postmedication-washout baseline IOP 22–38?mmHg were randomized to implantation of one, two, or three stents. Ocular hypotensive medication was to be used if postoperative IOP exceeded 18?mmHg. Results: A total of 38 subjects were implanted with one stent, 41 subjects with two stents, and 40 subjects with three stents. Both month 12 IOP reduction ≥20% without ocular hypotensive medication vs baseline unmedicated IOP and month 12 unmedicated IOP ≤18?mmHg were achieved by 89.2%, 90.2%, and 92.1% of one-, two-, and three-stent eyes, respectively. Furthermore, 64.9%, 85.4%, and 92.1% of the three respective groups achieved unmedicated IOP?≤15?mmHg. Over the 18-month follow-up period, medication was required in seven one-stent subjects, four two-stent subjects, and three three-stent subjects. At 18?months, mean unmedicated IOP was 15.9±0.9?mmHg in one-stent subjects, 14.1±1.0?mmHg in two-stent subjects, and 12.2±1.1?mmHg in three-stent subjects. Month 18 IOP reduction was significantly greater ( P <0.001) with implantation of each additional stent, with mean differences in reduction of 1.84?mmHg (95% confidence interval 0.96–2.73) for three-stent vs two-stent groups and 1.73?mmHg (95% confidence interval 0.83–2.64) for two-stent vs one-stent groups. Adverse events through 18?months were limited to cataract progression with best-corrected visual acuity loss and subsequent cataract surgery. Conclusion: In this series, implantation of each additional stent resulted in significantly greater IOP reduction with reduced medication use. Titratability of stents as a sole procedure was shown to be effective and safe, with sustained effect through 18?months postoperatively in OAG not controlled with medication.
机译:目的:评估一,二或三个小梁微旁路支架在原发性开角型青光眼(OAG)不能通过眼压治疗药物控制的眼睛中的安全性和有效性。总共119名受试者在术后18个月接受了随访。材料和方法:将药物眼压(IOP)18–30?mmHg和药物后冲洗基线IOP 22–38?HgHg的受试者随机分配为植入一个,两个或三个支架。如果术后眼压超过18?mmHg,应使用降压药。结果:总共38位受试者植入了一个支架,41位受试者植入了两个支架,40位受试者植入了三个支架。与不使用眼底降压药的情况相比,不使用基线降压药的第12个月的IOP降低≥20%,使用单支架,二支架和三支架的眼,分别达到89.2%,90.2%和92.1%的基线无药物的IOP≤18?mmHg,分别。此外,三组中分别有64.9%,85.4%和92.1%的未用药IOP?≤15?mmHg。在18个月的随访期内,七名单支架受试者,四名两支架受试者和三名三支架受试者需要药物治疗。在18个月时,单支架受试者的平均非药物IOP为15.9±0.9?mmHg,两支架受试者为14.1±1.0?mmHg,三支架受试者为12.2±1.1?mmHg。植入每个额外的支架后,第18个月的IOP降低明显更大(P <0.001),三支架组与两支架组和1.73?mmHg的平均降低差异为1.84?mmHg(95%置信区间0.96-2.73)。两支架组与一支架组的置信区间(95%置信区间0.83–2.64)。到18个月为止的不良事件仅限于白内障进展,且矫正视力最佳,随后进行白内障手术。结论:在这个系列中,每增加一个支架的植入都会显着提高IOP的减少,同时减少用药。支架的可滴定性是唯一有效且安全的方法,在未经药物控制的OAG术后18个月可以持续有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号